StockData
Royalty Pharma plc logo

Royalty Pharma plc (RPRX) stock

RPRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 8/3050% above fair value
$68.68+0.16 (+0.23%)

Close on Nov 17, 2026Market cap $39.49BP/E 39.0Yield –

Royalty Pharma pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

Royalty Pharma's pe ratio was 39.8× on Nov 11, 2026, against 24.6× a year earlier. Over the last 5 years it ranged from 10.9× to 360.3×, with a median of 28.1×.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 202639.8×+16.1
2025Dec 31, 202523.7×+12.5
2024Dec 31, 202411.2×−60.8
2023Dec 29, 202372.0×+38.0
2022Dec 30, 202234.1×+13.4
2021Dec 31, 202120.6×–

More Royalty Pharma figures

See a number that looks wrong?